Eli Lilly plans to bring its experimental oral weight-loss drug orforpligron in India as it sees scope for such products in the world's most populous nation, a senior executive said on Thursday.

Celltrion Inc. said in a regulatory filing in South Korea on Tuesday its U.S. subsidiary has acquired Imclone Systems LLC from Eli Lilly in the United States for $330 million.

Eli Lilly's Mounjaro helped children and adolescents aged 10 to 17 years with type 2 diabetes manage their blood sugar better and lose weight, according to trial results presented at a medical meet...

The drug, which is meant to treat Type 2 diabetes, was compared with Novo Nordisk's oral semaglutide, and showed greater improvements in blood sugar levels, known as A1C, and greater weight loss.

Lilly CEO Dave Ricks explains why pricing dynamics in the U.K. make it a very unattractive place for Lilly to invest.

Eli Lilly on Tuesday said it will spend $5 billion to build a manufacturing facility in Goochland County, Virginia, to boost production capacity for targeted cancer drugs and other treatments — the...

Plan is part of the drugmaker's pledge to bolster its domestic medicine production with four new pharmaceutical manufacturing sites.

Eli Lilly 's experimental weight-loss pill could be fast-tracked under a one- to two-month review process recently launched by the U.S. Food and Drug Administration, several Wall Street analysts said.

The new generation of effective weight loss drugs has generated billions of dollars for industry leaders Eli Lilly (LLY -0.96%) and Novo Nordisk (NVO 1.39%), and opened the door for companies such ...

Eli Lilly shares move past the 50-day SMA as weight-loss drug data, rising sales and pipeline momentum fuel optimism.

Eli Lilly and Novo Nordisk are both preparing to launch obesity pills in the U.S. next year. Lilly expects results from a head-to-head trial of its pill orforglipron versus Novo's oral semaglutide ...

For a while, it seemed that nothing could go wrong for Eli Lilly (LLY 0.23%). Surging sales for Lilly's type 2 diabetes drug Mounjaro and great expectations for its obesity drug Zepbound fueled mas...

What's a monster stock? In my book, it's a company that's already delivered enormous growth to investors, and considering opportunities ahead, this player should continue to roar higher in the year...

Eli Lilly and Company (NYSE:LLY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants Jacob Van Naarden - Executive VP & President of Lilly On...

In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamusti...